Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
about
Vancomycin revisited - 60 years laterGenetic and molecular predictors of high vancomycin MIC in Staphylococcus aureus bacteremia isolates.Impact of Molecular Epidemiology and Reduced Susceptibility to Glycopeptides and Daptomycin on Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.Impact of prior healthcare-associated exposure on clinical and molecular characterization of methicillin-susceptible Staphylococcus aureus bacteremia: results from a retrospective cohort studyRelationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.Vancomycin minimum inhibitory concentrations and lethality in Staphylococcus aureus bacteremiaReduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection.Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections.Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.Genomic exploration of sequential clinical isolates reveals a distinctive molecular signature of persistent Staphylococcus aureus bacteraemia
P2860
Q34433066-76CB66D2-3E86-4D42-BF54-C19779DD2CCEQ35035799-1CF2C141-9CC8-4BA0-98F2-0E7DC0526CF1Q35752011-A54CB7A7-C51F-40D5-8C65-28890523FC36Q36152264-23E34A94-9617-4894-8A9E-AC266CF06C28Q38690127-1087D3E7-1CDA-4924-BB6D-FE954BECBE53Q38780029-449EA1B7-2952-41C4-A4E7-E5B92D6FF9BAQ38993110-1C2D7E79-5E79-4D89-B1FC-96058AC7EDC9Q40200466-3DF0F353-A292-4EAE-9563-793CF57A2A86Q40264307-6CD98CE0-59F6-4A8B-AF8F-5AAE893416DBQ40441139-21BD0B93-B389-47A2-AE65-7AD922B70A77Q40845477-E0B14C3A-23FF-489C-91AC-391E77254A8CQ40891194-0A81FF08-B548-4EA7-827C-648C378B1E0CQ42223222-9102C0F9-478F-4B27-8FA5-D6A72EAAB7F8Q58716354-DFBCB07A-CBCE-476C-8A6B-9701DE30B069
P2860
Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Vancomycin minimum inhibitory ...... hylococcus aureus bacteraemia.
@en
Vancomycin minimum inhibitory ...... hylococcus aureus bacteraemia.
@nl
type
label
Vancomycin minimum inhibitory ...... hylococcus aureus bacteraemia.
@en
Vancomycin minimum inhibitory ...... hylococcus aureus bacteraemia.
@nl
prefLabel
Vancomycin minimum inhibitory ...... hylococcus aureus bacteraemia.
@en
Vancomycin minimum inhibitory ...... hylococcus aureus bacteraemia.
@nl
P2093
P356
P1476
Vancomycin minimum inhibitory ...... hylococcus aureus bacteraemia.
@en
P2093
J D Turnidge
J O Robinson
M V N O'Sullivan
N E Holmes
P D R Johnson
S A Roberts
S J C Warren
T L Anderson
W J Munckhof
P304
P356
10.1111/1469-0691.12168
P577
2013-02-26T00:00:00Z